Helperby Therapeutics Addresses A Clear Unmet Need In Areas Of Significant Market Value
Helperby has three development candidates in clinical trials:
- HY-001 (Urinary Tract Infection) - Phase I completed
- HY-004 (Nasal MRSA) - Phase II
- HY-007 (Consumer Antibacterial) - Market ready
View full development candidate pipeline ยป
We are actively seeking business development partners.
We help other companies to rescue their antibiotics from resistance
Helperby has worked with companies which are in different stages of development.
News
23 Mar 2020 • BBC reports Coronavirus continuing to develop globally
25 Jan 2020 • The Guardian Announces ‘Sepsis deaths around the world are twice as high as previously thought’.
15 Feb 2019 • Antibiotic-Resistance-Plan-To-Fight-Urgent-Global-Threat
27 Jul 2018 • Develop New Antibiotics or Face Fines, Drug Firms Told
Key Papers